Donald W Burt, MD
Otolaryngology · Bakersfield
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Owns Morgan Hill Surgery Center, LP: Accreditation Lapsed
Offices
1 location · Kern County Hospital Authority · 264 clinicians in this group
Looking this up.
Hospitals listed: Adventist Health Bakersfield · Kern Medical Center. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Burt’s office at (661) 326-2000 to ask if they take your plan before you enroll.
California Medical Board record
Licence A40654 · Current
Licensed to practise in California · since 1984 · expires 2028-01-31 · Autonomous University of Guadalajara Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- Morgan Hill Surgery Center, LPAmbulatory Surgery Center · Morgan Hill, CA3.7% owner · accredited by AAAHCAccreditation Lapsed1 inspection · last 2012-08-03
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Adventist Health BakersfieldBakersfield, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Adventist Health, which runs 28 hospitals in 3 statesPatients rate it 3 of 5 · 68% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.146, Oct 2024 – Sep 2025
- Kern Medical CenterBakersfield, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPatients rate it 2 of 5 · 60% would definitely recommend itOverall rating: 1 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.3, Oct 2024 – Sep 2025
See every measure and the patient survey for Adventist Health Bakersfield
Behind the star rating — Deaths: 0 better, 5 the same, 2 worse of 7 measures. Safety: 1 better, 5 the same, 0 worse of 6 measures. Readmissions: 0 better, 6 the same, 3 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.146 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.08 (0.1 to 2.06) · 1,228 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.82 (0.48 to 1.17) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 190.57 (143.33 to 237.81) · 109 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 3.4 · 35 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 10.1 · 89 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.7 · 220 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 14.1 · 308 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 18.7 · 462 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.8 · 387 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 3,695 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.15 (0 to 0.36) · 5,306 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.27 (0.07 to 0.47) · 5,505 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.32 (1.18 to 5.46) · 1,081 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.99 (0.32 to 3.66) · 215 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.39 (0.84 to 3.93) · 1,043 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.06 (0 to 16.24) · 219 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.3 (1.28 to 9.31) · 212 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.67 (0.18 to 3.16) · 263 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.15 (0 to 0.81) · 4,389 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.9 · 87 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.306 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 1.102 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.409 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.699 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.9 · 452 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.7 · 730 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 14 · 235 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -2 · 367 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 26.1 · 504 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 18.5 · 920 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.3 (4.5 to 8.7) · 216 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.4 (8.6 to 14.7) · 216 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.4 · 67 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 18.5 · 204 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (9.9 to 17.8) · 170 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.7 to 1.2) · 406 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,099 patients answered, 17% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 3 |
| Room was "always" clean | 70% |
| Nurses "always" communicated well | 74% |
| Doctors "always" communicated well | 73% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 68% |
| Doctors "always" listened carefully | 71% |
| Doctors "always" treated them with courtesy and respect | 81% |
| Patients who gave a rating of "9" or "10" (high) | 66% |
| Staff "always" explained new medications | 73% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 47% |
| "YES", patients would definitely recommend the hospital | 68% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
See every measure and the patient survey for Kern Medical Center
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.3 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.77 (0.73 to 2.82) · 318 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.01 (0.58 to 1.43) | No different | Jul 2022 – Jun 2024 |
| Death rate for heart failure patientsComplications and deaths | 11.5 · 26 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 17.7 · 37 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13.1 · 48 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 4.4 · 436 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,854 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.04 to 0.47) · 1,749 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.19 (1.78 to 6.59) · 415 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.65 (0 to 3.37) · 104 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.37 (0.74 to 4.01) · 418 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.6 (1.14 to 20.06) · 118 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.79 (1.58 to 9.99) · 106 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.69 (0.19 to 3.2) · 79 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.33 (0 to 1.29) · 1,271 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.02 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.034 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.686 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.46 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.6 · 45 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -35.8 · 34 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -8.9 · 33 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.8 · 31 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.4 (3.5 to 8.5) · 36 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.6 (7.3 to 15.4) · 36 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21 · 26 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.8 to 18.4) · 57 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 93 cases | No different | Jan 2024 – Dec 2024 |
What patients said (319 patients answered, 7% of those asked)
| Cleanliness | 3 |
| Nurse communication | 1 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 2 |
| Room was "always" clean | 64% |
| Nurses "always" communicated well | 69% |
| Doctors "always" communicated well | 69% |
| Staff "always" explained | 53% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 83% |
| Doctors "always" explained things so they could understand | 63% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 76% |
| Patients who gave a rating of "9" or "10" (high) | 61% |
| Staff "always" explained new medications | 62% |
| Nurses "always" explained things so they could understand | 62% |
| Nurses "always" listened carefully | 65% |
| Nurses "always" treated them with courtesy and respect | 79% |
| "Always" quiet at night | 32% |
| "YES", patients would definitely recommend the hospital | 60% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 88% |
Original Medicare doctor bills
$1,105
Medicare paid this office $1,105 for 11 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
11 Original Medicare patients in 2024. Average age 77 · Health risk score 1.18. At or below the middle of the specialty; the typical otolaryngology clinician is at 1.19.
The office billed $3,085, Medicare allowed $1,386 and paid $1,105; for 16 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 11 | 16 | 77 | 1.18 | $3,085 | $1,105 |
| 2018 | 289 | 1,405 | 74 | 1.22 | $164,874 | $81,511 |
| 2017 | 312 | 2,153 | 74 | 1.22 | $282,173 | $96,254 |
| 2016 | 309 | 2,368 | 74 | 1.17 | $300,939 | $97,804 |
| 2015 | 324 | 1,807 | 74 | 1.23 | $278,868 | $100,606 |
| 2014 | 379 | 2,905 | 74 | 1.03 | $410,840 | $141,517 |
| 2013 | 426 | 3,108 | 74 | 1.16 | $440,219 | $160,517 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2018: 6 services
| Short return visit (20+ min) | 233 | $37,949 | $67 |
| New patient visit (45+ min) | 99 | $15,116 | $153 |
| Removal of impacted ear wax | 115 | $9,305 | $47 |
| Comprehensive hearing and speech recognition test | 23 | $827 | $36 |
| Test for balance and posture | 11 | $385 | $35 |
| Test for eardrum and muscle function | 16 | $321 | $20 |
2017: 9 services
| Short return visit (20+ min) | 257 | $35,401 | $62 |
| New patient visit (45+ min) | 132 | $17,348 | $131 |
| Removal of impacted ear wax | 107 | $7,587 | $43 |
| Test for balance and posture | 12 | $1,153 | $96 |
| Comprehensive hearing and speech recognition test | 35 | $1,133 | $32 |
| Test for eardrum and muscle function | 31 | $570 | $18 |
| Injection of drug or substance under skin or into muscle | 14 | $387 | $23 |
| Injection, methylprednisolone acetate, 80 mg | 14 | $126 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 14 | $3 | None |
2016: 11 services
| Short return visit (20+ min) | 237 | $35,602 | $60 |
| New patient visit (45+ min) | 131 | $17,669 | $135 |
| Removal of impacted ear wax | 114 | $7,511 | $42 |
| Test for allergy using allergenic extract | 13 | $5,993 | $7 |
| Test for balance and posture | 19 | $2,014 | $101 |
| Comprehensive hearing and speech recognition test | 31 | $1,040 | $34 |
| Test for eardrum and muscle function | 26 | $490 | $19 |
| Test to assess balance during warm and cool irrigation in both ears | 11 | $401 | $36 |
| Injection of drug or substance under skin or into muscle | 11 | $389 | $24 |
| Injection, methylprednisolone acetate, 80 mg | 12 | $116 | None |
| Injection, dexamethasone sodium phosphate, 1 mg | 12 | $4 | None |
2015: 10 services
| Short return visit (20+ min) | 265 | $39,901 | $61 |
| New patient visit (45+ min) | 134 | $18,401 | $137 |
| Removal of impacted ear wax | 99 | $6,856 | $42 |
| Test for balance and posture | 27 | $2,631 | $94 |
| Assessment and recording of balance system during irrigation of both ears | 20 | $1,228 | $15 |
| Comprehensive hearing and speech recognition test | 31 | $1,054 | $34 |
| Test for eardrum and muscle function | 29 | $552 | $19 |
| Test to measure rate of airflow | 12 | $497 | $35 |
| Test for abnormal eye movement using 3 positions with recording | 21 | $449 | $21 |
| Test for abnormal eye movement with recording | 21 | $378 | $18 |
2014: 14 services
| Short return visit (20+ min) | 310 | $46,633 | $60 |
| New patient visit (45+ min) | 151 | $20,526 | $136 |
| Removal of impacted ear wax | 124 | $6,986 | $38 |
| Professional service for preparation and provision of 1 or more antigens | 12 | $6,053 | $13 |
| Test for abnormal eye movement using a rotating chair | 22 | $4,679 | $106 |
| Test for balance and posture | 31 | $3,237 | $104 |
| Comprehensive hearing and speech recognition test | 56 | $1,819 | $32 |
| Assessment and recording of balance system during irrigation of both ears | 26 | $1,515 | $15 |
| Test for eardrum and muscle function | 57 | $1,045 | $18 |
| Test for abnormal eye movement with recording | 28 | $754 | $27 |
| Test for abnormal eye movement using 3 positions with recording | 28 | $650 | $23 |
| Administration of influenza virus vaccine | 15 | $467 | $31 |
| Test for abnormal eye movement using a moving target that moves back and forth with recording | 11 | $394 | $20 |
| Influenza virus vaccine, split virus, for intramuscular use (agriflu) | 15 | $368 | $25 |
2013: 14 services
| Short return visit (20+ min) | 326 | $52,963 | $62 |
| New patient visit (45+ min) | 206 | $28,368 | $138 |
| Removal of impacted ear wax | 139 | $9,455 | $44 |
| Test for abnormal eye movement using a rotating chair | 25 | $5,400 | $108 |
| Complex control of nose bleed | 11 | $3,136 | $209 |
| Test for balance and posture | 28 | $2,950 | $105 |
| Professional service for multiple injections of allergen | 12 | $2,696 | $10 |
| Diagnostic exam of voice box using a flexible endoscope | 17 | $2,011 | $106 |
| Comprehensive hearing and speech recognition test | 54 | $1,800 | $33 |
| Assessment and recording of balance system during irrigation of both ears | 25 | $1,441 | $15 |
| Test for eardrum and muscle function | 48 | $893 | $18 |
| Test for abnormal eye movement with recording | 25 | $715 | $29 |
| Test for abnormal eye movement using 3 positions with recording | 25 | $638 | $26 |
| Injection of drug or substance under skin or into muscle | 11 | $387 | $24 |
Medicaid work
$5,228 in 2024
Medicaid paid $5,228 for 52 billed services this clinician did in 2024, up to 20 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| New patient visit (30+ min) | 52 | $5,228 |
| 2024 | 52 | 1 | 20 | $5,228 |
Drugs they prescribed that Part D paid
$15,978
Pharmacies billed $15,978 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 267) in 2024. At or below the middle of the specialty; the typical otolaryngology clinician is at 4%.
215 generic and fewer than 11 brand-name prescriptions · $15,978 in drug cost · 63 antibiotic prescriptions to 35 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Ciprofloxacin-Dexamethasone | 48 | $5,778 | $120 |
| Ventolin Hfa | 15 | $871 | $58 |
| Cefdinir | 41 | $605 | $15 |
| Fluconazole | 12 | $268 | $22 |
| Azithromycin | 12 | $186 | $15 |
See all 7 drugs
| Ciprofloxacin-Dexamethasone | 48 | $5,778 | $120 |
| Ventolin Hfa | 15 | $871 | $58 |
| Cefdinir | 41 | $605 | $15 |
| Fluconazole | 12 | $268 | $22 |
| Azithromycin | 12 | $186 | $15 |
| Moxifloxacin | 13 | $153 | $12 |
| Methylprednisolone | 15 | $77 | $5 |
Year by year
| 2024 | 267 | 95 | 0% (0) | None | $15,978 |
| 2023 | 144 | 21 | 0% (0) | None | $10,298 |
| 2022 | 140 | 18 | 0% (0) | None | $16,095 |
| 2021 | 180 | 20 | 0% (0) | 32% | $24,192 |
| 2020 | 179 | 36 | 0% (0) | 38% | $22,892 |
| 2019 | 333 | 85 | 0% (0) | 32% | $36,937 |
| 2018 | 563 | 153 | 4% (22) | 23% | $44,887 |
| 2017 | 650 | 185 | 2% (13) | 22% | $47,100 |
| 2016 | 770 | 171 | 2% (15) | 28% | $61,098 |
| 2015 | 851 | 180 | 3% (21) | 32% | $74,573 |
| 2014 | 950 | 215 | 3% (29) | 28% | $75,821 |
| 2013 | 780 | 199 | 3% (21) | None | $62,862 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Ciprofloxacin-Dexamethasone | 15 | $1,884 | $126 |
| Ventolin Hfa | 15 | $926 | $62 |
| Cefdinir | 18 | $369 | $21 |
| Azithromycin | 13 | $117 | $9 |
2022: 2 drugs
| Cefdinir | 20 | $795 | $40 |
| Ventolin Hfa | 12 | $741 | $62 |
2021: 4 drugs
| Spiriva | 12 | $6,136 | $511 |
| Ventolin Hfa | 13 | $1,074 | $83 |
| Cefdinir | 17 | $435 | $26 |
| Diazepam | 12 | $63 | $5 |
2020: 7 drugs
| Spiriva | 12 | $5,778 | $482 |
| Flovent Hfa | 14 | $4,184 | $299 |
| Ciprodex | 13 | $3,252 | $250 |
| Ventolin Hfa | 15 | $1,409 | $94 |
| Cefdinir | 30 | $871 | $29 |
| Alprazolam | 11 | $86 | $8 |
| Diazepam | 14 | $72 | $5 |
2019: 9 drugs
| Flovent Hfa | 24 | $8,394 | $350 |
| Ciprodex | 25 | $5,972 | $239 |
| Spiriva | 12 | $5,517 | $460 |
| Tobramycin-Dexamethasone | 19 | $2,280 | $120 |
| Cefdinir | 64 | $1,854 | $29 |
| Ventolin Hfa | 15 | $898 | $60 |
| Montelukast | 37 | $379 | $10 |
| Omeprazole | 12 | $76 | $6 |
| Diazepam | 12 | $52 | $4 |
2018: 19 drugs
| Androgel | 11 | $7,252 | $659 |
| Flovent Hfa | 20 | $6,551 | $328 |
| Spiriva | 11 | $4,701 | $427 |
| Ciprodex | 20 | $4,420 | $221 |
| Cefdinir | 115 | $3,965 | $34 |
| Tobramycin-Dexamethasone | 25 | $2,479 | $99 |
| Ventolin Hfa | 19 | $1,144 | $60 |
| Azelastine | 11 | $686 | $62 |
| Montelukast | 41 | $600 | $15 |
| Fluconazole | 14 | $591 | $42 |
| Hydrocortisone | 11 | $532 | $48 |
| Valacyclovir | 12 | $366 | $31 |
| Omeprazole | 28 | $218 | $8 |
| Ranitidine | 23 | $209 | $9 |
| Hydrocodone-Acetaminophen | 19 | $117 | $6 |
| Zolpidem | 12 | $92 | $8 |
| Alprazolam | 11 | $70 | $6 |
| Diazepam | 12 | $49 | $4 |
| Prednisone | 16 | $48 | $3 |
2017: 19 drugs
| Ciprodex | 36 | $7,328 | $204 |
| Androgel | 11 | $6,111 | $556 |
| Advair Diskus | 16 | $5,777 | $361 |
| Cefdinir | 138 | $4,069 | $29 |
| Qvar | 12 | $2,523 | $210 |
| Pilocarpine | 11 | $1,750 | $159 |
| Tobramycin-Dexamethasone | 16 | $1,571 | $98 |
| Proair Hfa | 18 | $1,348 | $75 |
| Omeprazole | 74 | $792 | $11 |
| Esomeprazole Magnesium | 13 | $739 | $57 |
| Azelastine | 18 | $669 | $37 |
| Hydrocortisone | 13 | $616 | $47 |
| Montelukast | 38 | $360 | $9 |
| Fluticasone Propionate | 18 | $207 | $11 |
| Mupirocin | 13 | $126 | $10 |
| Prednisone | 21 | $72 | $3 |
| Hydrocodone-Acetaminophen | 11 | $65 | $6 |
| Diazepam | 22 | $59 | $3 |
| Alprazolam | 11 | $57 | $5 |
2016: 22 drugs
| Ciprodex | 34 | $6,496 | $191 |
| Tobramycin-Dexamethasone | 35 | $4,823 | $138 |
| Cefdinir | 111 | $3,464 | $31 |
| Flovent Hfa | 12 | $2,565 | $214 |
| Pilocarpine | 13 | $1,717 | $132 |
| Azelastine | 28 | $1,248 | $45 |
| Proair Hfa | 22 | $1,240 | $56 |
| Proair Respiclick | 14 | $715 | $51 |
| Hydrocortisone | 12 | $437 | $36 |
| Montelukast | 47 | $435 | $9 |
| Ofloxacin | 11 | $359 | $33 |
| Valacyclovir | 11 | $349 | $32 |
| Omeprazole | 52 | $333 | $6 |
| Mupirocin | 30 | $283 | $9 |
| Fluticasone Propionate | 25 | $227 | $9 |
| Zolpidem | 13 | $197 | $15 |
| Clindamycin | 12 | $160 | $13 |
| Prednisone | 26 | $123 | $5 |
| Triamterene-Hydrochlorothiazid | 11 | $116 | $11 |
| Alprazolam | 20 | $113 | $6 |
| Hydrocodone-Acetaminophen | 13 | $113 | $9 |
| Diazepam | 18 | $77 | $4 |
2015: 24 drugs
| Ciprodex | 59 | $10,380 | $176 |
| Tobramycin-Dexamethasone | 49 | $6,415 | $131 |
| Androgel | 13 | $6,057 | $466 |
| Cefdinir | 108 | $3,940 | $36 |
| Nasonex | 17 | $3,653 | $215 |
| Foradil | 15 | $3,464 | $231 |
| Dymista | 11 | $1,864 | $169 |
| Azelastine | 29 | $1,782 | $61 |
| Valacyclovir | 20 | $1,089 | $54 |
| Proair Hfa | 12 | $616 | $51 |
| Clotrimazole | 12 | $508 | $42 |
| Hydrocortisone | 13 | $468 | $36 |
| Montelukast | 44 | $424 | $10 |
| Synthroid | 13 | $409 | $31 |
| Omeprazole | 43 | $385 | $9 |
| Mupirocin | 36 | $297 | $8 |
| Fluticasone Propionate | 22 | $210 | $10 |
| Ciprofloxacin | 21 | $186 | $9 |
| Ranitidine | 16 | $129 | $8 |
| Prednisone | 25 | $128 | $5 |
| Alprazolam | 17 | $105 | $6 |
| Diazepam | 19 | $94 | $5 |
| Hydrocodone-Acetaminophen | 13 | $72 | $6 |
| Zolpidem | 11 | $43 | $4 |
2014: 32 drugs
| Ciprodex | 56 | $8,914 | $159 |
| Tobramycin-Dexamethasone | 63 | $7,563 | $120 |
| Cefdinir | 149 | $6,734 | $45 |
| Androgel | 13 | $5,227 | $402 |
| Nexium | 11 | $3,579 | $325 |
| Azelastine | 40 | $3,020 | $76 |
| Foradil | 13 | $2,750 | $212 |
| Nasonex | 14 | $2,404 | $172 |
| Astepro | 14 | $2,305 | $165 |
| Singulair | 12 | $2,236 | $186 |
| Xyzal | 13 | $1,254 | $96 |
| Amox Tr-Potassium Clavulanate | 11 | $836 | $76 |
| Montelukast | 34 | $772 | $23 |
| Clotrimazole-Betamethasone | 17 | $756 | $44 |
| Valacyclovir | 14 | $628 | $45 |
| Fluconazole | 17 | $587 | $35 |
| Omeprazole | 45 | $520 | $12 |
| Hydrocortisone | 13 | $477 | $37 |
| Nystatin | 16 | $396 | $25 |
| Synthroid | 13 | $384 | $30 |
| Ciprofloxacin | 32 | $348 | $11 |
| Mupirocin | 28 | $323 | $12 |
| Fluticasone Propionate | 18 | $303 | $17 |
| Acyclovir | 21 | $236 | $11 |
| Hydrocodone-Acetaminophen | 27 | $196 | $7 |
| Triamterene-Hydrochlorothiazid | 15 | $145 | $10 |
| Azithromycin | 12 | $127 | $11 |
| Prednisone | 26 | $112 | $4 |
| Diazepam | 25 | $98 | $4 |
| Alprazolam | 15 | $84 | $6 |
| Ranitidine | 11 | $75 | $7 |
| Zolpidem | 14 | $62 | $4 |
2013: 23 drugs
| Tobramycin-Dexamethasone | 62 | $9,399 | $152 |
| Ciprodex | 47 | $7,027 | $150 |
| Cefdinir | 129 | $5,909 | $46 |
| Androgel | 13 | $4,692 | $361 |
| Astepro | 18 | $3,196 | $178 |
| Singulair | 18 | $2,998 | $167 |
| Avelox | 11 | $2,808 | $255 |
| Dexilant | 20 | $1,550 | $78 |
| Omeprazole | 61 | $1,077 | $18 |
| Xyzal | 12 | $1,067 | $89 |
| Hydrocortisone | 13 | $482 | $37 |
| Mupirocin | 38 | $457 | $12 |
| Nystatin | 12 | $444 | $37 |
| Montelukast | 16 | $435 | $27 |
| Amox Tr-Potassium Clavulanate | 16 | $327 | $20 |
| Acyclovir | 25 | $320 | $13 |
| Synthroid | 13 | $317 | $24 |
| Clotrimazole | 13 | $130 | $10 |
| Ciprofloxacin | 19 | $127 | $7 |
| Hydrocodone-Acetaminophen | 19 | $125 | $7 |
| Ranitidine | 12 | $85 | $7 |
| Prednisone | 27 | $74 | $3 |
| Zolpidem | 14 | $68 | $5 |
Money from drug and device companies
$331 in 2025
| 2025 | 4 | 10 | None | $331 |
| 2021 | 1 | 1 | None | $36 |
| 2019 | 3 | 3 | None | $50 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Regeneron Healthcare Solutions | Dupixent | $154 | 6 payments
|
| Sanofi-Aventis U.S. | Dupixent | $99 | 1 payment
|
| Genzyme | Dupixent | $50 | 2 payments
|
| Greer Laboratories | Oralair | $29 | 1 payment
|
See all 10 published payments
| Regeneron Healthcare Solutions | Meals · 2025-12-12 | Dupixent | $32 |
| Regeneron Healthcare Solutions | Meals · 2025-12-04 | Dupixent | $37 |
| Regeneron Healthcare Solutions | Meals · 2025-11-07 | Dupixent | $22 |
| Regeneron Healthcare Solutions | Meals · 2025-09-29 | Dupixent | $16 |
| Regeneron Healthcare Solutions | Meals · 2025-09-19 | Dupixent | $24 |
| Sanofi-Aventis U.S. | Education · 2025-09-02 | Dupixent | $99 |
| Regeneron Healthcare Solutions | Meals · 2025-08-29 | Dupixent | $22 |
| Genzyme | Meals · 2025-07-31 | Dupixent | $29 |
| Greer Laboratories | Meals · 2025-06-23 | Oralair | $29 |
| Genzyme | Meals · 2025-06-05 | Dupixent | $21 |
See earlier years (2021, 2019)
2021: $36
| Intersect ENT | Sinuva | $36 | 1 payment
|
2019: $50
| Smith+Nephew | Coblation - Turbinate Wands | $18 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $16 | 1 payment
|
| OptiNose US | Xhance | $16 | 1 payment
|
Professional record
- NPI
- 1942244108
- Licence
- CA A40654California A40654: Current · expires 2028-01-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA A406545
- Taxonomy
- Federal specialty code 207YX0602X (207YX0602X)
- Mailing address
- 18181 Butterfield Blvd Ste 120, Morgan Hill, CA, 95037
- NPI first listed
- 2006-06-16
- NPI last updated
- 2019-02-04
This is when the NPI record was last certified, not a medical board exam.